New Strategies for Assessment of the Persistence of Viable Bacilli in

Status Recruiting

Clinical Trial Summary

Current diagnostic tools such as interferon gamma release assay (IGRA) and purified protein derivative (PPD) can not distinguish patients with latent tuberculosis infection (LTBI) and persistence of live mycobacteria. This inability to rule out living mycobacteria in patients investigated for LTBI leads to unnecessary and potentially harmful treatment regimes all around the globe. The goal of this observational study is to identify candidate biomarkers for viable bacilli in latent tuberculosis in order to decrease the use of unnecessary and ineffective antibiotic treatment.

Clinical Trial Description

Tuberculosis (TB) is the second leading cause of death due to a single infectious agent, with the main burden in resource-limited settings and in vulnerable populations. It is estimated that approximately 25% of the global population is infected with TB. LTBI is a condition where the mycobacteria rests within the body instead of creating active disease. About half of the active TB cases develop within 2 years of exposure and the other half reactivates as distant as several decades post exposure. Persistence of viable bacilli is a prerequisite for the reactivation of TB. Through sampling of peripheral blood the investigators will investigate how selected cytokines, enzyme activity and gene expression changes during course of treatment, 4-6 months, and during follow up, 1 year. These patterns will be compared to the patterns of patients with: latent TB without treatment, active TB with treatment as well as healthy controls. Samples will be drawn at 0, 1, 6 and 12 months, after treatment initialization when applicable. Healthy controls will only be sampled once. Most of the analysis will be performed on TB-antigen stimulated blood. The investigators hypothesize that there is a substantial fraction of latent TB patients who do not harbor live mycobacteria and that this is reflected in study outcome measures when given treatment. Furthermore, the investigators hypothesize that this fraction of latent TB patients will resemble healthy controls in terms of outcome measures whereas their counterpart, latent TB patients harboring living bacteria, will not. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05621343
Study type	Observational [Patient Registry]
Source	Region Skane
Contact	Petter Holmberg, PhD student
Phone	+4640333108
Email	petter.holmberg@med.lu.se
Status	Recruiting
Phase
Start date	December 21, 2021
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05073926` - Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
Not yet recruiting	`NCT04428294` - Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation	Phase 4
Completed	`NCT02276755` - Vitamin D Supplementation in TB Prevention	Phase 3
Withdrawn	`NCT03498534` - Evaluation of Diabetes Control and Effect on Transmission and Development of Tuberculosis	Phase 4
Active, not recruiting	`NCT03988933` - 2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB.	Phase 2
Recruiting	`NCT06022146` - TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts	Phase 3
Active, not recruiting	`NCT04188041` - Improving Rhode Island's Tuberculosis Preventive Services in Primary Care	N/A
Recruiting	`NCT03730181` - Tuberculosis Clinical Trials Consortium Study 35	Phase 1/Phase 2
Completed	`NCT01967134` - Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis	Phase 1
Completed	`NCT00257907` - Immune Response to Mycobacterium Tuberculosis Infection
Recruiting	`NCT05756582` - Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students
Active, not recruiting	`NCT04557176` - TB Screening Improves Preventive Therapy Uptake	N/A
Completed	`NCT02119130` - Quantiferon Gold Test for Detecting Tuberculosis (TB) Infection in HIV/AIDS Patients in South Africa	N/A
Not yet recruiting	`NCT06281834` - Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention	Phase 1
Not yet recruiting	`NCT02512484` - Improving the Detection of Active Tuberculosis in Accident and Emergency Departments	N/A
Completed	`NCT00763295` - Is Tuberculin Skin Testing Effective in Screening for Latent Tuberculosis in Patients With HIV?	N/A
Completed	`NCT01850043` - The Epidemiology of TST Change in Korea	N/A
Completed	`NCT02090374` - Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen	N/A
Completed	`NCT02073669` - Latent Tuberculosis in Second Generation Immigrants From High Risk Countries Compare to Low-risk Young Israeli Adults	N/A
Completed	`NCT02880982` - Trial of Vitamin D Supplementation in Cape Town Primary Schoolchildren	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

New Strategies for Assessment of the Persistence of Viable Bacilli in Latent and Active Tuberculosis — TB-LIVE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms